Dentsply Sirona downgraded by Evercore ISI with a new price target
$XRAY
Medical/Dental Instruments
Health Care
Evercore ISI downgraded Dentsply Sirona from Outperform to In-line and set a new price target of $20.00
Get the next $XRAY alert in real time by email
Get the next $XRAY alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $XRAY
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2025 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/13/2025 | Buy → Hold | Needham | |
| 2/14/2025 | $20.00 | Equal Weight | Wells Fargo |
| 1/23/2025 | $30.00 → $20.00 | Buy → Hold | Jefferies |
| 1/7/2025 | $20.00 | Outperform → In-line | Evercore ISI |
| 12/4/2024 | $21.00 | Neutral | Mizuho |
| 11/7/2024 | Outperform → Market Perform | Leerink Partners | |
| 10/25/2024 | $34.00 → $29.00 | Buy | Needham |
Dentsply Sirona to Host First Quarter Conference Call on May 8th
CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se
Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2025
CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 11, 2025, at 3:00 pm ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and
Dentsply Sirona downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00
Dentsply Sirona downgraded by Needham
Needham downgraded Dentsply Sirona from Buy to Hold
Wells Fargo initiated coverage on Dentsply Sirona with a new price target
Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00
Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)
4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Director Vergis Janet S. was granted 87 shares, increasing direct ownership by 0.29% to 30,101 units (SEC Form 4)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Director Varon Leslie F was granted 87 shares, increasing direct ownership by 0.26% to 33,807 units (SEC Form 4)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
EVP, Corp Dev, GC & Secretary Rosenzweig Richard C was granted 628 shares, increasing direct ownership by 0.76% to 83,452 units (SEC Form 4)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
SEC Form DEFA14A filed by DENTSPLY SIRONA Inc.
DEFA14A - DENTSPLY SIRONA Inc. (0000818479) (Filer)
SEC Form DEFA14A filed by DENTSPLY SIRONA Inc.
DEFA14A - DENTSPLY SIRONA Inc. (0000818479) (Filer)
SEC Form DEF 14A filed by DENTSPLY SIRONA Inc.
DEF 14A - DENTSPLY SIRONA Inc. (0000818479) (Filer)
Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se
Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members
CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B
Dentsply Sirona Appoints Herman V. Cueto Interim Chief Financial Officer
CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company's next CFO. "We are fortunate to have Herman joining us as interim CFO during this important time in Dentsply Sirona's history," said Simon Campion, President and Chief Executive Officer. "Herman
Dentsply Sirona to Host First Quarter Conference Call on May 8th
CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf
Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook
FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial resul
Dentsply Sirona Initiates Review of Strategic Alternatives for Wellspect Healthcare
CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business ("Wellspect"). Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered improved organic sales growth in recent years, including mid-to-high single digit growth for 2023 and through the first three quarters of 2024. The business is well-positioned in the larg
Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SEC Form SC 13G filed by DENTSPLY SIRONA Inc.
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SEC Form SC 13G filed by DENTSPLY SIRONA Inc.
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)